GlassScriptPhysician profile
Bruce W Berger
NPI 1558324657
$1,623.14
in general payments reported to CMS, 2019-2025
27 companies · $97.87 in 2025
The $97.87 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $911 · 2020: $147 · 2021: $145 · 2022: $170 · 2023: $41.45 · 2024: $112 · 2025: $97.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $139 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $139.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $208.90 | 2019-2020 | |
| Neotract INC. | $132.74 | 2019 | |
| Sumitomo Pharma America, INC. | $129.93 | 2023-2024 | Orgovyx, Gemtesa |
| Boston Scientific Corporation | $119.04 | 2019-2020 | |
| Amgen INC. | $116.17 | 2019-2020 | |
| Janssen Biotech, INC. | $102.84 | 2019-2021 | |
| Comsort, INC | $100.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $97.87 | 2025 | Erleada |
| Urogen Pharma, INC. | $76.05 | 2022 | |
| Abbott Laboratories | $71.26 | 2022 | |
| Endo Pharmaceuticals INC. | $66.69 | 2019 | |
| Abbvie INC. | $50.86 | 2019-2020 | |
| Myovant Sciences INC. | $50.57 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $50.56 | 2019 | |
| Ferring Pharmaceuticals INC. | $42.23 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $40.74 | 2019-2020 | |
| Rochester Medical Corporation | $30.34 | 2020 | |
| Telix Pharmaceuticals | $23.31 | 2023 | Illuccix |
| Allergan, INC. | $23.27 | 2019 | |
| Metuchen Pharmaceuticals | $16.77 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $15.92 | 2019 | |
| Blue Earth Diagnostics | $15.19 | 2019 | |
| Myriad Genetic Laboratories, INC. | $15.01 | 2021 | |
| Merck Sharp & Dohme LLC | $14.64 | 2021 | |
| Pfizer INC. | $12.24 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$361,837.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.